Business Context and Reporting Period
This Form 8-K filing by Biocardia, Inc. (BCDA) is dated April 1, 2025. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
- Stockholders' Equity: $837,000 as of December 31, 2024.
- Listing Requirement: Minimum stockholders' equity of $2.5 million under Nasdaq Listing Rule 5550(b)(1).
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for these metrics.
- Debt and Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes and Listing Status
The Company is currently non-compliant with Nasdaq's minimum stockholders' equity requirement. While the stock continues to trade under the symbol "BCDA" on the Nasdaq Capital Market, the Company has been notified of its failure to meet the $2.5 million equity threshold.
Outlook, Risks, and Management Commentary
- Compliance Plan Deadline: The Company must submit a plan to regain compliance to Nasdaq by May 16, 2025.
- Extension Possibility: If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from April 1, 2025, to achieve compliance.
- Management Intent: The Company intends to submit a plan to regain compliance. If the plan is rejected, the Company may request a hearing before a Nasdaq Hearings Panel.
- Risks: There is a risk that the Company may not meet the equity requirement in the required timeframe, that Nasdaq may not grant relief, or that the Company may ultimately fail to meet listing requirements, potentially leading to delisting.
Investor Verification Checklist
- Verify the Company's stockholders' equity balance as of December 31, 2024, in the most recent Form 10-K.
- Monitor the submission of the compliance plan to Nasdaq by the May 16, 2025 deadline.
- Review the Company's Annual Report on Form 10-K (filed March 26, 2025) for detailed financial condition and risk factors.
- Track any subsequent announcements regarding Nasdaq's acceptance or rejection of the compliance plan.